Why Owens & Minor's Shares Crashed 17.5% Today
What happened
After the company reported second-quarter 2018 sales and earnings that fell shy of what industry watchers wanted, Owens & Minor's (NYSE: OMI) shares lost 17.5% of their value on Tuesday.
So what
The medical supply company's second-quarter revenue and EPS clocked in at $2.46 billion and $0.32, respectively. The top line grew 8.4% from last year; however, it was still $10 million shy of Wall Street analysts' forecast. The EPS figure missed estimates by $0.14 per share.
The sales increase was helped by the acquisition of Byram Healthcare, which added $128 million in sales, and two months of revenue resulting from its acquisition of Halyard's surgical and infection business, which contributed $136.9 million net of eliminations tied to sales to Owens & Minor's other businesses.
Now what
Owens & Minor is in the midst of a revamp that includes integrating those acquisitions in a way that shaves its costs and boosts its bottom line. The company's full-year guidance is for adjusted net income per diluted share of between $1.40 to $1.50, and management says it's "confident" in its "ability to achieve a double digit, year-over-year adjusted earnings growth rate next year."
Nevertheless, investors don't appear willing to give management the benefit of the doubt. In the past year, the company's been battling weaker pricing, margin headwinds, and supply bottlenecks. Perhaps a wait-and-see approach to this stock is warranted until the all-clear is sounded.
10 stocks we like better than Owens & MinorWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Owens & Minor wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 6, 2018
Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.